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example of the antidepressants, a drug group with rapid growth and 
large differences between the originator and generic prices.
Patients (or Materials) and Methods: National ATC/DDD wholesale 
data and the Estonian Health Insurance Fund (EHIF) prescription 
database were used to analyze the antidepressant utilization patterns.
Results: According to the national medicines use data, the total con-
sumption of antidepressants (ADs) was 17.8 defined daily doses per 
1000 inhabitants per day (DID) in Estonia in 2011. During the past 
12 years, the use of these medicines has increased 3-fold (from 5.3 
to 17.8 DID) but is still modest compared with the Nordic countries 
(average consumption of ADs was 77 DID in 2010). The SSRIs con-
stitute about two thirds of the total ADs consumption in Estonia, 
with 11.5 DID in 2011. On the active substance level, there was 
a rapid increase in the use of escitalopram. The average price of 1 
DDD of escitaloprm is 1.01€ for the originator versus 0.30€ for the 
generic. The originator accounts for 20% of the total sale. This is 
similar to the other SSRIs. This may cause substantial patient copay-
ment. We analyzed prescription data from the EHIF to describe in 
detail the use of escitalopram during last years, taking into account 
the patient factors, the prescriber, the cost, and the adherence to treat-
ment expressed via the number of filled prescriptions. The cheapest 
generic generated a 75% lower patient copayment in comparison 
with the originator. In 2011, one half of the new users filled only 1 
prescription. 27% of the new users filling ≥ 2 prescriptions started 
treatment with the originator product, one half of them switched 
treatment to a generic later. Predictors of the originator use and 
adherence were also analyzed.
Conclusion: The average proportion of generic use for the active sub-
stances that have generics on the market is ~60% in Estonia. Where 
the price difference is substantial, the generics fast engage ~80% of 
the market, but even here approximately one fifth of the patients 
stay on the originator product. Reasons and consequences of this 
for the adherence need to be explored further to guide interventions.
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Introduction: The introduction of tyrosinekinase inhibitors (TKI) 
brought a major advance for survival of chronic myeloid leukaemia 
(CML) patients, but as with any other chronic therapy, issues of 
tolerance and adherence are of paramount importance for successful 
clinical outcome.
Patients (or Materials) and Methods: We conducted a structured 
interview concerning patients’ subjective view of their condition and 
history, including the MARS (Medication Adherence Report Scale) 
and BMQ (Beliefs about Medicines Questionnaire) scales to assess 
patients’ perception of their medication and their self-reported adher-
ence. The results were then correlated with trough blood levels of 
imatinib and nilotinib measured as part of routine therapeutic drug 
monitoring to identify patients most at risk of nonadherent behavior. 
We included a total of 38 consecutive patients treated with TKI for 
at least 3 months coming for a regular checkup at clinicof Hemato-
oncology Department of the Faculty Hospital in Olomouc, Czech 
Republic. The population included 20 male and 18 female patients, 
average age 59.6 years (34–75); 21% of patients live alone, 79% 
live with a partner or family, and 18% were university educated. 
Most patients (26 [68%]) were treated with imatinib; dasatinib 
and nilotinib accounted for 16% (6) each. Patients were on average 
7.8 years from diagnosis (0.33–12). On average, patients had 6.15 
years of experience with their current medication; for 82% of them, 
the current TKI was first-line treatment.
Results: Despite the fact that most patients (60%) reported having 
experienced some adverse effects, these were rarely perceived as seri-
ous or bothersome enough to lead to nonadherence. Patients scored 
consistently high on the necessity scale of the BMQ, but most showed 
at least 1 significant concern on the concern scale (87% with at least 
1 score of ≥ 3). The MARS scores showed high adherence – 79% 
scored 24 or 25 out of a 25-point maximum. This is in line with 
the fact that nearly all (95%) of the patients reported that they feel 
sufficiently educated about their disease and treatment. Results from 
questionnaires and demographic data were then correlated with TKI 
trough blood levels and response to the treatment with TKI to analyze 
prognostic impact of nonadherence. Final results will be presented 
at the conference.
Conclusion: Thanks to well-conducted patient education, CML 
patients on TKI perceive the necessity of their treatment, as measured 
by the BMQ scale, and have good adherence rates, as measured by the 
BMQ and MARS scales and TKI trough blood levels, despite experi-
encing a significant number of side effects. Efficient patient education 
at our center that has resulted in better adherence level than reported 
in the previous studies is 1 of the most important preconditions for 
achievement of optimal response to TKI treatment.
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Introduction: Orally disintegrating tablets (ODTs) disintegrate 
immediately in the mouth, and thus patients can consume them 
with little or without any water. These characteristics of ODTs are 
beneficial for patients who have difficulty swallowing conventional 
tablets (CTs) and also for patients with diseases in which water intake 
is restricted. In this study, we evaluated clinical disintegration time of 
17 ODTs that are currently available for clinical use and determined 
the amount of water required to ingest ODTs and CTs.
Patients (or Materials) and Methods: The clinical disintegration time 
was measured for 17 ODT products. Each tablet was placed on the 
tongues of healthy volunteers (n = 18), and disintegrated in their oral 
cavities. The clinical disintegration time of each ODT was measured 
by the investigator with a stopwatch. The residue in the oral cavity 
was removed and rinsed from the mouth with water after the test. 
In the measurement of the volume of water for ingesting of CTs and 
ODTs, which did not include any active pharmaceutical ingredients, 
all volunteers (n = 26) were asked to drink water while consuming 
CTs; while in the case of ODTs, they were asked to drink water after 
the ODT disintegrated in their oral cavity. They freely filled the cup 
with water from the 500-mL bottle and then drank the volume of 
water required to consume each tablet. The amount of water was 
measured using the weight of the cup and bottle. All study protocols 
were approved by the ethics committee of the University of Shizuoka.
Results: To validate the method for measuring the clinical disintegra-
tion time of ODTs, the subjects were randomly assigned to 3 groups, 
and the clinical disintegration times of 2 ODTs were measured. No 
significant difference was observed in the clinical disintegration time 
of each ODT among the 3 groups, which indicated the reproducibility 
